Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Marchpole Update

23 Mar 2005 07:00

Marchpole Holdings PLC23 March 2005 23 March 2005 Marchpole Holdings plc ("the Company") Marchpole Update Marchpole Holdings plc, which designs, produces and sells high quality clothingand accessories for six world class brands (Yves Saint Laurent, Boateng,Jean-Charles de Castelbajac ("JCC") and Jean-Charles de Castelbajac / Rossignol,Emmanuel Ungaro and Ungaro. The Company is pleased to announce that its differences with Ozwald Boateng andhis company have been resolved by the current court proceedings and aninjunction has been granted preventing Bespoke Couture Limited from sellingsuits and other items through a discount outlet, established without referenceto the Company. The dispute involved a number of issues. In April 2004 Ozwald Boateng andBespoke Couture alleged breach of contract and threatened termination of itsdiffusion licence with the Company. The allegation was made in respect of theCompany withholding a compensation payment under an agreement first made inOctober 2002 that provided for the termination or conclusion of an O-Z designagreement with Debenhams and subsequent removal of O-Z stock, which the Companyalleged was to take place by 1 September 2003. This agreement was concludedseparately to the main licence contract. As stock did exist at this time theCompany withheld payments and sought an amicable conclusion. Under threat ofcourt proceedings Bespoke Couture withdrew its first threat to terminate andwhen a second threat was made this was successfully resisted with BespokeCouture having to withdraw its threat and costs were awarded to the Company.Following recent court proceedings it was found that the Company should make thecompensation payment from March 2004, the date that the O-Z product was finallyremoved from Debenhams, a position which the Company has always been prepared toconsider. During November 2004, the Company became aware of an Ozwald Boateng discountoutlet operating at Bicester Village. the Company contended that this was inbreach of the main licence agreement and this was confirmed by yesterday'sjudgment. The injunction granted, as Bespoke Couture has accepted, will meanthat Bespoke Couture will have to close this outlet. Costs were awarded reflecting success on the various issues with the detailedfinancial implications to be determined at a later date. Greg Tufnell, Chief Executive commented: "Throughout this process we have always sought to reassure our shareholders thatthese issues would not impact our main licence agreement nor our financialprojections. The judgment handed down is consistent with these reassurances andI now look forward to focusing on the successful platform Marchpole has builtfor the Boateng brand" For further information contact: Marchpole Greg Tufnell - Chief Executive 020 7908 7700Michael Morris - Executive Director Shore Capital Alex Borrelli 020 7408 4090 Buchanan Tim Thompson / Nicola Cronk 020 7466 5000 Notes to editors: In September this year, Marchpole announced strong interim results for the sixmonths ended 2 October 2004, with operating profit up 194% to £2.6 million(2003: £0.9m) on increased turnover of £15.7 million (2003 : £8.0 million). This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th Feb 20197:00 amRNSBoard Change
25th Jan 201911:10 amRNSPublication of F-4
18th Jan 20197:00 amRNSNew Deferred Bonus Plan
15th Jan 20197:00 amRNSBGS-649 Phase 2b data to be Presented at ENDO 2019
27th Dec 201810:02 amRNSDirector/PDMR Shareholding
24th Dec 20187:00 amRNSDirector/PDMR Shareholding
18th Dec 20187:00 amRNSPositive results from safety extension study
17th Dec 20186:25 pmRNSPositive results from safety extension study
17th Dec 20183:44 pmRNSAIM Rule 17 Disclosure Statement
10th Dec 20187:00 amRNSPresentation at BMO Healthcare Conference
5th Dec 20181:09 pmRNSProposed combination of Mereo and OncoMed
26th Nov 20187:00 amRNSIssue of Warrants
5th Nov 20187:00 amRNSFirst patient dosed in Phase 2 study
31st Oct 20183:37 pmRNSTotal Voting Rights
15th Oct 20187:00 amRNSCompletion of Patient Enrolment in Phase 2b study
1st Oct 201810:00 amRNSRevised Credit Facility and Issue of Warrants
3rd Sep 20187:00 amRNSBlock Listing Application
31st Aug 20186:25 pmRNSCorrection to Issued Share Capital
8th Aug 20187:00 amRNSMereo BioPharma Interim Results 2018
23rd Jul 20187:00 amRNSExercise of Options
23rd Jul 20187:00 amRNSNotice of Interim Results
21st Jun 201812:52 pmRNSResult of Annual General Meeting
29th May 20187:00 amRNSSuccessful Completion of PrimaryBid Offer
25th May 20184:31 pmRNSPrimaryBid.com Offer
22nd May 20187:00 amRNSNotice of AGM
27th Apr 20187:00 amRNSGrant of Options
26th Apr 20187:00 amRNSUpdate on Offering & Application to List on Nasdaq
9th Apr 201811:34 amRNSOffering and Application to List on Nasdaq
6th Apr 20181:03 pmRNSResult of General Meeting
3rd Apr 20187:00 amRNSPublication of Annual Report
26th Mar 20187:00 amRNSMereo BioPharma Files for Proposed Global Offering
23rd Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSPUBLICATION OF NOTICE OF GENERAL MEETING
20th Mar 20187:00 amRNSMereo selected for oral presentation at ATS 2018
19th Mar 20187:00 amRNSMereo: Positive Top-Line Results for BGS-649
26th Feb 20187:00 amRNSMereo BioPharma Appoints Wills Hughes-Wilson
2nd Jan 20187:00 amRNS£10m credit facility drawdown & issue of warrants
18th Dec 20177:00 amRNSMereo Plans to Conduct Registered IPO in the US
13th Dec 20177:00 amRNSMereo BioPharma: Business Update
11th Dec 20177:00 amRNSPositive results from Phase 2 trial with BCT-197
13th Nov 20177:00 amRNSBPS-804 receives PRIME designation
6th Nov 201712:19 pmRNSHolding(s) in Company
30th Oct 20177:00 amRNSMereo announces agreement with AstraZeneca
18th Sep 20177:00 amRNSMereo to Present at Cantor Healthcare Conference
5th Sep 20177:00 amRNSUpdate on BGS-649 Phase 2b Study
22nd Aug 20179:17 amRNSIssue of Warrants
8th Aug 20177:12 amRNSInterim Results
3rd Jul 20177:00 amRNSNotice of Results
27th Jun 201711:23 amRNSResult of AGM
15th May 20177:00 amRNSUpdate on acumapimod Phase 2 Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.